A Look at Synopsys (SNPS) Valuation After Recent Share Price Volatility

Synopsys (SNPS) shares have drawn some attention as investors reflect on the company’s steady annual revenue and profit growth. The stock’s recent moves highlight how market participants are weighing those fundamentals against this year’s performance.

See our latest analysis for Synopsys.

Despite strong revenue and profit growth, Synopsys shares have seen some choppy trading lately, with a 7.1% one-week dip and a 22.3% drop over the last three months. Momentum has faded in the short term, and the one-year total shareholder return sits at -14.3%. Long-term holders have still nearly doubled their returns over five years.

If you’re looking for other tech names with potential, keep the momentum going and see the full list of innovation-driven opportunities in our tech and AI stocks screener: See the full list for free.

With Synopsys trading well below analysts’ average price target, but with recent results already reflecting robust growth, the key question for investors is whether there is untapped upside or if the market has already factored in its future gains.

Advertisement

Most Popular Narrative: 20.2% Undervalued

Synopsys last closed at $443.76, which is well below the most widely followed narrative’s fair value estimate of $556.40. This suggests substantial upside if the long-term expectations embedded in the narrative prove accurate. The following catalyst captures one of the key drivers behind this outlook.

The ongoing transformation towards SaaS, cloud-based EDA and Ansys product integration is expected to increase customer stickiness and shift more revenues to subscription and service models. This would improve revenue visibility and earnings consistency. It directly addresses operational headwinds and is likely underappreciated if the stock is undervalued.

Read the complete narrative.

What exactly justifies that high fair value? The story hinges on aggressive growth projections. Analysts are plugging in revenue and earnings assumptions rarely seen for established tech firms. Ever wondered what kind of financial forecast supports such a bold multiple? The underlying quantitative leaps may surprise you.

Result: Fair Value of $556.40 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, export restrictions and persistent headwinds in the Design IP segment could challenge Synopsys’ growth outlook and put pressure on its valuation narrative.

Find out about the key risks to this Synopsys narrative.

Another View: Multiple-Based Valuation Raises Questions

Looking through the lens of price-to-earnings, Synopsys trades at 70.7 times earnings, much higher than the US software industry average of 34.9 times and its peers at 47.2 times. Even compared to its fair ratio of 47.3 times, the current valuation looks stretched. Does this gap suggest hidden growth or a risk if market sentiment turns?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:SNPS PE Ratio as at Oct 2025
NasdaqGS:SNPS PE Ratio as at Oct 2025

Build Your Own Synopsys Narrative

If you think the story deserves a different perspective or want to test your own expectations, you can shape your own Synopsys narrative in just a few minutes. Do it your way.

A great starting point for your Synopsys research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Act now to target the best investment opportunities beyond Synopsys. If you want an edge, these unique stock lists put powerful trends right at your fingertips.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:SNPS

Synopsys

Provides design IP solutions in the semiconductor and electronics industries.

Moderate growth potential with mediocre balance sheet.

Advertisement

Weekly Picks

DA
davidlsander
OPTH logo
davidlsander on Optimi Health ·

OPTH: A licensed manufacturer already selling MDMA while peers still wait on trials

Fair Value:US$1259.6% undervalued
10 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HA
HarishPK
DOX logo
HarishPK on Amdocs ·

Why Amdocs is a high conviction Buy for me?

Fair Value:US$82.0328.6% undervalued
36 users have followed this narrative
3 users have commented on this narrative
12 users have liked this narrative
IV
SBMO logo
Ivoed on SBM Offshore ·

Why SBM Offshore’s €30 Share Price May Be Too Harsh On Its Backlog

Fair Value:€44.524.7% undervalued
22 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
CL
Clive_Thompson
6831 logo
Clive_Thompson on Green Tea Group ·

One of China's Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend

Fair Value:HK$8.719.3% undervalued
47 users have followed this narrative
3 users have commented on this narrative
20 users have liked this narrative

Updated Narratives

PE
RYTM logo
peter_4mgsy on Rhythm Pharmaceuticals ·

High-Growth Emerging Commercial Stage Biotech

Fair Value:US$13413.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WO
woodworthfund
RAIL logo
woodworthfund on FreightCar America ·

ALL ABOARD THE VALUE TRAIN: WHY $RAIL MIGHT BE HEADED NORTH - FREIGHTCAR AMERICA - Long term price target of $25

Fair Value:US$2568.4% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AS
AstrisCorporateAdvisory
268A logo
AstrisCorporateAdvisory on Rigaku Holdings ·

Capitalizing on rising semiconductor complexity

Fair Value:JP¥2.52k22.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28022.3% undervalued
287 users have followed this narrative
9 users have commented on this narrative
16 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.9120.5% overvalued
153 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
KI
AMZN logo
KiwiInvest on Amazon.com ·

Amazon's high growth, high tech segments propel its profits, while traditional segments plod along

Fair Value:US$475.0941.5% undervalued
173 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative